These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20184575)

  • 41. PPAR-γ action: it's all in your head.
    Myers MG; Burant CF
    Nat Med; 2011 May; 17(5):544-5. PubMed ID: 21546969
    [No Abstract]   [Full Text] [Related]  

  • 42. [Basic approach to choose anti-diabetic drugs].
    Hirukawa H; Kaku K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():626-31. PubMed ID: 21766672
    [No Abstract]   [Full Text] [Related]  

  • 43. Metabolic syndrome and bariatric surgery in stone disease etiology.
    Tasca A
    Curr Opin Urol; 2011 Mar; 21(2):129-33. PubMed ID: 21191301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Reactive-dystrophic processes in salivary glands (sialoadenoses) running on the background of metabolic syndrome].
    Afanas'ev VV; Striuk RI; Arutiunian SE; Eliseeva LV; Bychkov RA
    Stomatologiia (Mosk); 2011; 90(4):49-53. PubMed ID: 21983616
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Thiazolidinediones].
    Yamanouchi T
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():633-6. PubMed ID: 17458295
    [No Abstract]   [Full Text] [Related]  

  • 46. Obesity and the insulin resistance syndrome.
    Dunger DB
    Arch Dis Child; 2005 Jan; 90(1):1. PubMed ID: 15613499
    [No Abstract]   [Full Text] [Related]  

  • 47. Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes.
    Asrafuzzaman M; Cao Y; Afroz R; Kamato D; Gray S; Little PJ
    Biomed Pharmacother; 2017 May; 89():1242-1251. PubMed ID: 28320091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diabetes: Turning down galectin 3 to combat insulin resistance.
    Kingwell K
    Nat Rev Drug Discov; 2016 Dec; 16(1):18. PubMed ID: 28031565
    [No Abstract]   [Full Text] [Related]  

  • 49. Metabolic syndrome, insulin resistance, circadian disruption, antioxidants and pancreatic carcinoma: an overview.
    Giudice A; Crispo A; Massimiliano G; D'Arena G; Tecce MF; Grimaldi M; Amore A; Esposito E; Montella M
    J Gastrointestin Liver Dis; 2014 Mar; 23(1):73-7. PubMed ID: 24689100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Metabolic syndrome, obesity and urolithiasis].
    Traxer O; Safar H; Daudon M; Haymann JP
    Prog Urol; 2006 Sep; 16(4):418-20. PubMed ID: 17069032
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The metabolic syndrome and stroke: potential treatment approaches.
    Arenillas JF; Moro MA; Dávalos A
    Stroke; 2007 Jul; 38(7):2196-203. PubMed ID: 17540972
    [No Abstract]   [Full Text] [Related]  

  • 52. [Intracellular signal transduction of vascular injury in insulin resistance].
    Yoshizumi M; Ishizawa K; Izawa Y; Tamaki T
    Nihon Yakurigaku Zasshi; 2006 Sep; 128(3):147-52. PubMed ID: 16971777
    [No Abstract]   [Full Text] [Related]  

  • 53. The stressed patient with diabetes mellitus.
    Noble KA
    J Perianesth Nurs; 2005 Oct; 20(5):354-8; quiz 359-60. PubMed ID: 16246814
    [No Abstract]   [Full Text] [Related]  

  • 54. [Effects of ARB in metabolic syndrome].
    Kumagai H; Takimoto C; Iigaya K; Kamayachi T; Saruta T; Itoh H
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():599-606. PubMed ID: 17458289
    [No Abstract]   [Full Text] [Related]  

  • 55. Insulin resistance and metabolic syndrome: mechanisms and consequences.
    Schmidt AM
    Arterioscler Thromb Vasc Biol; 2012 Aug; 32(8):1753. PubMed ID: 22815339
    [No Abstract]   [Full Text] [Related]  

  • 56. Interplay of vascular phenotype and metabolic phenotype in populations with or without type 2 diabetes.
    Bosevski M
    Stroke; 2008 Nov; 39(11):e175; author reply e176. PubMed ID: 18802203
    [No Abstract]   [Full Text] [Related]  

  • 57. [Thiazolidine derivatives].
    Hosoda K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():636-40. PubMed ID: 21766674
    [No Abstract]   [Full Text] [Related]  

  • 58. Re: Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Assimos DG
    J Urol; 2015 Jun; 193(6):2008-9. PubMed ID: 25986800
    [No Abstract]   [Full Text] [Related]  

  • 59. [Insulin resistance-induced hypertension and perivascular nerves-an approach to elucidate the mechanisms involved].
    Takatori S; Zamami Y; Hashikawa-Hobara N; Kawasaki H
    Nihon Yakurigaku Zasshi; 2012 Feb; 139(2):70-4. PubMed ID: 22322931
    [No Abstract]   [Full Text] [Related]  

  • 60. Does the metabolic syndrome exist?
    Grundy SM
    Diabetes Care; 2006 Jul; 29(7):1689-92; discussion 1693-6. PubMed ID: 16801603
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.